A5055470614- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemostasis and retained surgical items
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood properties and coagulation
- Hemoglobinopathies and Related Disorders
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Clinical practice guidelines implementation
- Vascular anomalies and interventions
- Viral-associated cancers and disorders
- Iron Metabolism and Disorders
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Screening and Detection
- Lymphoma Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Phagocytosis and Immune Regulation
- Cancer-related gene regulation
- Liver Disease Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Liver Disease and Transplantation
Tulane University
2013-2024
University Medical Center New Orleans
2015-2023
Tulane Medical Center
2013-2016
Emicizumab is a recombinant, humanized, bispecific, monoclonal antibody that bridges activated factor IX and X to restore the function of deficient VIII. Treatment bleeding in patients with hemophilia inhibitors involves use bypassing agents (BPA).These molecules are also used for management breakthrough bleeds on prophylaxis emicizumab, increased concerns about risks combining two procoagulant drugs. Using thrombin generation assay, we tailored dosage prothrombin complex concentrate (APCC)...
Background Patients with congenital F actor XIII ( FXIII ) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of concentrates before during surgery lacking. The objective this study was to report plasma‐derived concentrate C orifact in U nited S tates; ibrogammin P other countries) patients undergoing procedures. Study Design Methods preoperative doses ranging from 25 40 /kg administered six major or minor surgeries. Results...
Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94-9027, Jivi, Bayer, Germany) site-specifically PEGylated, extended-half-life, recombinant FVIII, approved for use previously treated patients (PTPs) aged ≥12 years with haemophilia A. However, real-world evidence regarding routine clinical of damoctocog limited.HEM-POWR multinational, multicentre, non-interventional, prospective, postmarketing cohort study evaluating...
Hemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% pediatric patients with HB possess a severe form FIX (<1% activity). Treatment typically requires replacement therapy through the administration FIX. However, exogenous has limited functional half-life, and natural anticoagulant protein S (PS) inhibits activated (FIXa). PS ultimately limits thrombin formation, which coagulation. This regulation FIXa activity led us to test whether...
Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).To provide long-term real-world safety and effectiveness data rpFVIII management AHA episodes.US PASS (NCT02610127) was a multicentre, uncontrolled, open-label, post-marketing surveillance study conducted AHA. Data were collected retrospectively or prospectively 180 days after treatment. The primary outcome incidence treatment-related...